Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
02/16/2017 02/17/2017 02/20/2017 02/21/2017 02/22/2017 Date
76.2(c) 77(c) 76.7(c) 77.4(c) 77.8 Last
5 846 826 11 565 061 4 962 940 7 442 680 6 462 228 Volume
+0.53% +1.05% -0.39% +0.91% +0.52% Change
More quotes
Financials ($)
Sales 2017 48 441 M
EBIT 2017 11 334 M
Net income 2017 7 521 M
Debt 2017 16 963 M
Yield 2017 3,70%
Sales 2018 50 495 M
EBIT 2018 12 370 M
Net income 2018 8 697 M
Debt 2018 13 900 M
Yield 2018 3,90%
P/E ratio 2017 23,23
P/E ratio 2018 20,39
EV / Sales2017 4,54x
EV / Sales2018 4,29x
Capitalization 202 892 M
More Financials
Company
Novartis AG develops, manufactures, and markets healthcare products.It operates through the following segments: Pharmaceuticals, Alcon, Sandoz, and Corporate Activities.The Pharmaceuticals segment provides patent-protected prescription medicines.The Alcon segment offers surgical, ophthalmic... 
Sector
Pharmaceuticals
Calendar
02/28 | 10:00amShareholder meeting
More about the company
Surperformance© ratings of Novartis AG
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVARTIS AG
03:44p MANUFACTURING DELAY OF GENERIC DRUG : PFE) A Relief For Teva Pharmaceutical Ind..
02/16 JOHNSON & JOHNSON : Nancy-Ann DeParle and Dr. Scott Gottlieb Join Executives fro..
02/15 NOVARTIS : Sources Sought Notice - Alcon Wavecards
02/14 IMMUNICUM : Appoints Karin Hoogendoorn as Head of CMC
02/09 NOVARTIS : Patent Issued for Microscope-Less Wide Field-Of-View Surgical OCT Vis..
02/09 NOVARTIS : Patent Issued for Ocular Implant Delivery Systems and Methods (USPTO ..
02/09 NOVARTIS : Ampersand Capital Partners and 1315 Capital to Acquire Genoptix
02/08 NOVARTIS : Medical researchers using new tools to turn science fiction into scie..
02/06 New GlaxoSmithKline CEO prepares for R&D choices, potential deals
02/03 Microsoft, Coca-Cola, Novartis, L`Oral, Nokia and more Join Ethisphere`s Glob..
More news
Sector news : Pharmaceuticals - NEC
09:10p Genmab and J&J's cancer drug set for blockbuster sales this year
07:48pDJBAYER : Details Financing Plan for Monsanto Deal
05:58p EU regulators set to clear Dow, DuPont deal - sources
03:38p Covestro parent Bayer non-committal on any sale to industry peer
12:03pDJBAYER : CEO Confident Monsanto Purchase Will Be Approved by End of Year -- Updat..
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on NOVARTIS AG 
2016A trend reversal can be anticipated
More Strategies
Latest Tweets
10:39p Should Merck, BMS Fear Roche's Drug Becoming The I-O King? $AZN $BMY $JNJ $M.. 
10:33pShould Merck, BMS Fear Roche's Drug Becoming The I-O King?  
09:18p.@LittleMix's Jesy on top form and ready to flirt after her split with fiance.. 
04:24pSwiss pharma major #Roche "cannot hang on to" #breastcancer drug #Trastuzumab..
23
12:14pEU nod for Roche’s lung cancer drug Alecensa
1
More tweets
Qtime:234
News from SeekingAlpha
03:29p Momenta Delay Means Race For Copaxone Generic Is On
02/21 HEPATITIS B MARKET : Emerging Players Could Make The Difference
02/21 Merck Provides Keytruda For Bionomics Phase 1 Trial On Combination With BNC10..
02/21 VBL's lead product candidate successful in mid-stage thyroid cancer study; sh..
02/21 This Biotech ETF Looks Primed To Rally Again
Advertisement
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 30
Average target price 80,4 $
Spread / Average Target 4,9%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG3.51%202 892
JOHNSON & JOHNSON3.86%325 539
ROCHE HOLDING LTD.4.90%212 000
PFIZER INC.3.51%204 018
MERCK & CO., INC.11.23%180 537
SANOFI4.72%109 519
More Results